Novartis inks deal to make COVID-19 vaccine candidate


ZURICH: Novartis’s gene therapy unit AveXis has signed a manufacturing agreement to produce a novel genetic COVID-19 vaccine being developed by the U.S.-based Mass General Brigham health care system, a spokeswoman for the Swiss drugmaker said on Thursday. “The COVID-19 pandemic is the most urgent public health crisis of our time and we recognize the significance of evaluating the potential role of a gene-based vaccine,” said AveXis President Dave Lennon in a statement issued by Mass General Brigham’s Massachusetts Eye and Ear and Massachusetts General Hospital.